Navigation Links
Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting
Date:6/1/2009

mab may represent a valuable new approach to treating cancer," said Dr. Raghunadharao Digumarti, professor of medical oncology at the Nizams Institute of Medical Sciences and a Phase II bavituximab cancer trial investigator who presented the data at ASCO on behalf of the study team. "We are pleased with the response rates and progression free survival data seen in the initial group of breast cancer patients and look forward to reporting additional results from the entire Phase II breast cancer study later this year."

The primary objective of this multi-center, open-label Phase II study is to assess the overall response rate to bavituximab and docetaxel. In the trial's two-stage design, 15 patients with advanced breast cancer were enrolled in the first cohort. The 71% objective tumor response rate seen in the 14 evaluable patients in the first cohort compares favorably with historical response rates for docetaxel as solo therapy in advanced breast cancer patients and it exceeded the pre-specified primary endpoint needed to expand the trial. An additional 31 patients were then enrolled to achieve the planned study total of 46 patients overall. With patient enrollment complete, dosing and follow-up are continuing. The safety profile of bavituximab plus docetaxel in the study has been acceptable, with minor infusion reactions, epistaxis and nasal dryness among the most common reported bavituximab-related side effects. These did not require dose modification or treatment discontinuation.

Separately, Peregrine reported that researchers will present data at ASCO today from a Phase I study assessing the safety and pharmacokinetic (PK) properties of bavituximab as monotherapy in patients with advanced refractory cancers. This multi-center open label safety study is currently enrolling patients in the final cohort according to the initial study design. The study authors report on their experience with the first 25 patients in the st
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Clinical Data on Peregrines Bavituximab Cancer Program to Be Discussed in Two Presentations at 2009 ASCO Annual Meeting
2. Peregrine Pharmaceuticals Reports Positive Data in Second Phase II Bavituximab Breast Cancer Trial
3. Peregrine Pharmaceuticals Awarded New U.S. Patent Further Strengthening Its Anti-Phospholipid Patent Portfolio
4. Nature Medicine study shows Peregrines bavituximab can cure lethal virus infections
5. Peregrine Pharmaceuticals to Present at the Cowen and Company 29th Annual Health Care Conference
6. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study
7. Nature Medicine study shows Peregrines bavituximab can cure lethal virus infections
8. Peregrine Pharmaceuticals Mourns Loss of Chairman Thomas A. Waltz
9. Peregrine Pharmaceuticals Enters Into a Loan Agreement for up to $10 Million
10. Peregrine Pharmaceuticals to Report Second Quarter FY 2009 Financial Results
11. Peregrine Pharmaceuticals to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 19, 2014 Naurex Inc., a biopharmaceutical company ... diseases of the central nervous system, today announced that ... officer, will present at the 33 rd annual ... place at 3:00 p.m. PST on Tuesday, January 13, ... San Francisco, Calif. About ...
(Date:12/19/2014)... (PRWEB) December 18, 2014 ... nation’s leading specialty pharmacies, has an expanded team ... clinical pharmacy consultants for prescriber offices in their ... , “We have a variety of Regional ... example, those specializing in hepatitis C help prescribers ...
(Date:12/19/2014)... 18, 2014 iLab Solutions, the global ... of Siri Bryant as the new Director of Institutional ... Core Implementations. These two new leadership positions were created ... by ensuring that iLab continues to meet the needs ... four years, iLab has been deployed at over 450 ...
(Date:12/19/2014)... , Dec. 18, 2014 Egenix, Inc. is pleased ... elected Chairman of the Board, to succeed Donald Fresne ... but will continue as a member of the Board.  In ... added to the company over almost twenty years, the Board ... Board of Directors has established a Search Committee to find ...
Breaking Biology Technology:Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 2BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 3iLab Solutions Announces Two New Leadership Positions to Meet the Needs of Its Growing Customer Base 2
... of a three-part series focusing on the past, present and future of ... to WTNs interview with Nettles in March 2003. , , ... the next six to 12 months, what Dept. of Commerce initiatives would ... I had a meeting with Gov. Doyle a couple of weeks ...
... people who helped North Carolina and Los Angeles become ... of angel investors shared their most effective practices Tuesday ... ,Their techniques included educational programsbut you have to be ... the Council for Entrepreneurial Development , based in ...
... The second annual Wisconsin Entrepreneurs Conference got off to a ... treating at least a hundred entrepreneurs and industry representatives to ... The entrepreneurial boot camp was designed serve both veteran ... success from a panel of seasoned industrialists. , ,Our purpose ...
Cached Biology Technology:WTN exclusive interview with Commerce Secretary Cory Nettles (part 2) 2WTN exclusive interview with Commerce Secretary Cory Nettles (part 2) 3WTN exclusive interview with Commerce Secretary Cory Nettles (part 2) 4WTN exclusive interview with Commerce Secretary Cory Nettles (part 2) 5Experts share advice for Wisconsin entrepreneur programs 2Experts share advice for Wisconsin entrepreneur programs 3Experts share advice for Wisconsin entrepreneur programs 4Entrepreneurs get crash course for building a successful company 2Entrepreneurs get crash course for building a successful company 3
(Date:12/17/2014)... DUBLIN , Dec. 15, 2014 Research ... announced the addition of the "Samsung Galaxy ... Analysis" report to their offering. ... on a totally different sensing technology than the ... a fingerprint sensor in its product. ...
(Date:12/17/2014)... 2014 Research and Markets ( ... "Global Chemical Sensor Market 2015-2019" report ... http://photos.prnewswire.com/prnh/20130307/600769 One major trend upcoming ... medical sensors in biomedical applications. Chemical sensors help ... correct diagnosis during surgical procedures. The Global Chemical ...
(Date:12/11/2014)... Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the ... 2015-2019" report to their offering. ... is the adoption of multimodal biometric systems. Multimodal ... an individual for verification and identification purposes. This ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... developing new antibiotics, and a technique called solid-state NMR ... , That's the view of University of Michigan researcher ... that goal March 3 at the annual meeting of ... research group is using solid-state NMR to explore the ...
... the persistent riddles of the deadly 1918 Spanish influenza ... severity. Why were some municipalities such as St. Louis ... when both implemented similar public health measures? What made ... the National Institutes of Health (NIH), was not only ...
... found evidence for new genes involved in the development ... be published in the next issue of the journal ... in 4,000 volunteers. , Several genes were ... most interesting gene being ‘GALP?which could affect the development ...
Cached Biology News:Natural antibiotics yield secrets to atom-level imaging technique 2Natural antibiotics yield secrets to atom-level imaging technique 3Rapid response was crucial to containing the 1918 flu pandemic 2Rapid response was crucial to containing the 1918 flu pandemic 3Rapid response was crucial to containing the 1918 flu pandemic 4Study examines genetic risk factors for Alzheimer's disease 2
Smac/DIABLO (mouse) (CT) rabbit polyclonal antibody...
... Rabbit polyclonal to Taura Syndrome ... for all tested applications). ... Synthetic peptide: VTNSEGSTIL MNDIPITNQN VVLSKNVTDN ... corresponding to N terminal amino ...
Purified Mouse anti-Hu Actopaxin (pS8) Storage Temperature: Refrigerate(2 to 8C)...
... The FastPlax Antibody is used to detect ... the surface of infected cells as early ... basis of the FastPlax Titer Kit, which ... 25-48 hours. The FastPlax Antibody ...
Biology Products: